top of page

Resverlogix will focus on the prevention and treatment of Post COVID-19 Conditions


Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.


The company’s new focus on patients with Post COVID-19 Conditions, colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflects the compelling opportunity for apabetalone to benefit long-COVID patients along with guidance from the US Food and Drug Administration.


Following the recent FDA meeting, Dr. Michael Sweeney, Senior VP, Clinical Development for Resverlogix, stated: “We are grateful to the FDA for the feedback and suggestions provided in our recent Type C meeting, and we look forward to continuing to work with regulators in our evaluation of apabetalone’s safety and efficacy in treating Post COVID-19 Conditions.”


InvestmentPitch Media

SOURCE


Recent Posts

See All
bottom of page